title: Ciprofloxacin-encapsulated poly(DL-lactide-co-glycolide) nanoparticles and its antibacterial activity.
abstract: The aim of this study was to prepare ciprofloxacin HCl (CIP)-encapsulated poly(dl-lactide-co-glycolide) (PLGA) copolymer nanoparticles and its antibacterial potential was evaluated with pathogenic bacteria, Escherichia coli (E. coli), in vitro and in vivo. CIP-encapsulated nanoparticles of PLGA were prepared by multiple emulsion solvent evaporation method. PLGA nanoparticles showed spherical shapes with particle sizes around 100-300 nm. Loading efficiency was lower than 50% (w/w) because of water-solubility properties of CIP. At drug release study, CIP showed initial burst effect for 12 h and then continuously released for 2 weeks. At in vitro antibacterial activity test, CIP-encapsulated nanoparticles showed relatively lower antibacterial activity compared to free CIP due to the sustained release characteristics of nanoparticles. However, CIP-encapsulated PLGA nanoparticles (doses: 25 mg CIP/kg of mice) effectively inhibited the growth of bacteria due to the sustained release characteristics of nanoparticles, while free CIP was less effective on the inhibition of bacterial growth. These results indicated that CIP-encapsulated PLGA nanoparticles have superior effectiveness to inhibit the growth of bacteria in vivo.
authors.affiliation: Department of Polymer Science and Engineering, Sunchon National University, Suncheon, Jeonnam 540-742, Republic of Korea.
authors.forename: Young-Il
authors.initials: YI
authors.lastname: Jeong
authors.forename: Hee-Sam
authors.initials: HS
authors.lastname: Na
authors.forename: Dong-Hyuk
authors.initials: DH
authors.lastname: Seo
authors.forename: Dong-Gon
authors.initials: DG
authors.lastname: Kim
authors.forename: Hyun-Chul
authors.initials: HC
authors.lastname: Lee
authors.forename: Mi-Kyeong
authors.initials: MK
authors.lastname: Jang
authors.forename: Sang-Kwon
authors.initials: SK
authors.lastname: Na
authors.forename: Sung-Hee
authors.initials: SH
authors.lastname: Roh
authors.forename: Sun-Il
authors.initials: SI
authors.lastname: Kim
authors.forename: Jae-Woon
authors.initials: JW
authors.lastname: Nah
mesh_terms: D000818:Animals; D000900:Anti-Bacterial Agents / Q000737:chemistry / Q000494:pharmacology*; D002626:Chemistry, Pharmaceutical; D002939:Ciprofloxacin / Q000737:chemistry / Q000494:pharmacology*; D003692:Delayed-Action Preparations; D004337:Drug Carriers; D004339:Drug Compounding; D004926:Escherichia coli / Q000187:drug effects / Q000254:growth & development; D007700:Kinetics; D019344:Lactic Acid / Q000737:chemistry*; D051379:Mice; D008813:Mice, Inbred ICR; D008826:Microbial Sensitivity Tests; D053758:Nanoparticles; D010316:Particle Size; D011100:Polyglycolic Acid / Q000737:chemistry*; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D012995:Solubility; D013678:Technology, Pharmaceutical / Q000379:methods
chemical_list: D000900:Anti-Bacterial Agents; D003692:Delayed-Action Preparations; D004337:Drug Carriers; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011100:Polyglycolic Acid; D019344:Lactic Acid; D002939:Ciprofloxacin